Pharmacokinetic/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated With 25 Mg of Sunitinib.

Pharmacokinetic/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated with 25 mg of Sunitinib.

Filed under: Drug and Alcohol Rehabilitation

Case Rep Oncol. 2012 Sep; 5(3): 627-32
Noda S, Kageyama S, Tsuru T, Kubota S, Yoshida T, Okamoto K, Okada Y, Morita SY, Terada T

Sunitinib has been approved for the treatment of advanced and/or metastatic renal cell carcinoma (RCC). Information on the dosage adjustment of sunitinib for patients undergoing hemodialysis is limited. Especially, efficacy and tolerance of sunitinib at a low dose in such patients are not fully understood. Thus, we examined the effect of hemodialysis on the pharmacokinetics, safety and efficacy of 25 mg of sunitinib. The patient was a 66-year-old man diagnosed with RCC and undergoing hemodialysis. He was treated with sunitinib at 25 mg daily for 4 weeks of a 6-week cycle. There were little differences in the AUC(0-24 h) of sunitinib and its major active metabolite SU12662 on day 17 (on hemodialysis) and day 18 (off hemodialysis) of the first cycle. The total sunitinib concentration (sunitinib and SU12662) was approximately 50 ng/ml at a steady state in every cycle. The patient’s genotype was wild type for ABCG2 421C>A, which is associated with increased sunitinib exposure. In the following two cycles of sunitinib, computed tomography scan showed a partial response of the lung metastasis. During the first cycle, the patient developed grade 2 thrombocytopenia and leukocytopenia. After four cycles of treatment, the patient developed grade 3 fatigue and the sunitinib treatment was discontinued. Our patient on hemodialysis could be safely and effectively treated with 25 mg of sunitinib, and a total sunitinib concentration of about 50 ng/ml was maintained. The pharmacokinetics of sunitinib and SU12662 were rarely affected by hemodialysis. Therapeutic drug monitoring could be helpful during sunitinib therapy, especially in a specific population.
HubMed – drug

 

Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor.

Filed under: Drug and Alcohol Rehabilitation

Bioinformation. 2012; 8(25): 1249-54
Chatterjee S, Bhattacharjee B

Angiogenesis refers to the formation of new blood vessels, controlled by certain chemicals, which on stimulation repairs damaged cells or form new ones. Other chemicals, called angiogenesis inhibitors, signal the process to stop, having only mild side effects and are non toxic to most healthy cells. In our study, attempt was made to find potent anti-angiogenic inhibitor (pazopanib was considered as a reference drug) for vascular endothelial growth factor receptor (VEGFR-1/FLT-1), which served as a molecular target, using natural agents targeting biological processes important in cancer. Hundreds of natural molecules were initially screened based on lipinski’s rule of five and the satisfying ones were taken for receptor-ligand interaction study using docking tools like HEX and quantum. Around fifteen molecules were taken as lead molecule and their binding pocket on VEGF was analyzed using SwissPDBviewer and Q-site finder. The investigational drug pazopanib was found to be interacting with leucine 32 and glutamine 30 in terms of hydrogen bond with the distance of 1.86 and 2.49 A0 respectively. Ames test for the molecules was predicted for probability of mutagenicity on molecular systems such as blood, cardiovascular system, gastrointestinal system; kidney, liver and lung were considered for further screening of the molecules. The natural molecules curcumin, epigallocatechin gallate (EGCG), barrigtozenol and finasteride were showing reliable interaction with VEGFR and their pharmacokinetics parameters were comparatively good than the pazopanib. The dietary product curcumin and EGCG can be cancer chemopreventive agents and the natural molecules barringtozenol and finasteride can be effective inhibitors for VEGFR.
HubMed – drug

 

Prediction of protein-mannose binding sites using random forest.

Filed under: Drug and Alcohol Rehabilitation

Bioinformation. 2012; 8(24): 1202-5
Khare H, Ratnaparkhi V, Chavan S, Jayraman V

Mannose is an abundant cell surface monosaccharide and has an important role in many biochemical processes. It binds to a great diversity of receptor proteins. In this study we have employed Random Forest for prediction of mannose binding sites. Mannosebinding site is taken to be a sphere around the centroid of the ligand and the sphere is subdivided into different layers and atom wise and residue wise features were extracted for each layer. The method achieves 95.59 % of accuracy using Random Forest with 10 fold cross validation. Prediction of mannose binding site analysis will be quite useful in drug design.
HubMed – drug

 

Anti hyperglycaemic study of natural inhibitors for Insulin receptor.

Filed under: Drug and Alcohol Rehabilitation

Bioinformation. 2012; 8(24): 1195-201
Chatterjee S, Narasimhaiah AL, Kundu S, Anand S

Diabetes is a metabolic disorder associated with either improper functioning of the beta-cells or wherein cells fail to use insulin properly. Insulin, the principal hormone regulates uptake of glucose from the blood into most of the cells except central nervous system. Therefore, deficiency of insulin or the insensitivity of its receptors plays a key role in all forms of diabetes. In the present work, attempt has been made to find out plant sources which show anti hyperglycaemic activity (AhG) (i.e. compounds that bring down the blood glucose level in the body). Ayurvedic plants showing AhG activity formed the basis of our study by using the platform of Computer Aided Drug Designing (CADD). Among 600 plants showing AhG activity, 500 compounds were selected and screened, out of which 243 compounds showed drug likeness property that can be used as therapeutic ligand/drug. Initial screening of such compounds was done based on their drug likeness or biochemical properties. Dynamic interaction of these molecules was captured through Protein-Ligand study. It also gave an insight of the binding pockets involved. Bench marking of all the parameters were done using the diabetic inhibitor drug, Glipizide. Pharmacokinetic studies of the compounds such as Aloins, Capparisine, Funiculosin and Rhein exhibited less toxicity on various levels of the body. As a conclusion these ligands can lay a foundation for a better anti-diabetic therapy. ABBREVIATIONS: AhG – Anti hyperglycaemic, CADD – Computer Aided Drug Designing.
HubMed – drug

 

More Drug And Alcohol Rehabilitation Information…